Intracellular fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis

Molecular Therapy

Volumn 2, Issue 4, 2000, Pages 348-358

  Hyer, Marc L ^a   Voelkel Johnson, Christina ^a   Rubinchik, Semyon ^a   Dong, Jian Yun ^a   Norris, James S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenovirus; Apoptosis; Fas ligand; Gene therapy; Prostate

Indexed keywords

ADENOVIRIDAE; MURINAE;

FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PHOTOPROTEIN;

ADENOVIRUS; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CONFOCAL MICROSCOPY; CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ADENOVIRIDAE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034296761     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0139     Document Type: Article

References (43)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. (1999). Cancer statistics [see comments]. CA Cancer J. Clin. 49: 8-31.
2. Konety, B. R., and Getzenberg, R. H. (1997). Novel therapies for advanced prostate cancer. Semin. Urol. Oncol. 15: 33-42.
3. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., 61nd Henderson, D. R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57: 2559-2563.
4. Hrouda, D., Perry, M., and Dalgleish, A. G. (1999). Gene therapy for prostate cancer. Semin. Oncol. 26: 455-471.
5. Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T., and Nagata, S. (1994). Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6: 1567-1574.
6. Suda, T., and Nagata, S. (1994). Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 179: 873-879.
7. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. (1995). A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270: 7795-7798.
8. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995). FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
9. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996). Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815.
10. Muzio, M., et al. (1996). FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 81 7-827.
11. Sasaki, Y., Ahmed, H., Takeuchi, T., Moriyama, N., and Kawabe, K. (1998). Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer. Br. J. Urol. 81: 852-855.
12. Xerri, L., Devilard, E., Hassoun, J., Mawas, C., and Birg, F. (1997). Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol. Pathol. 50: 87-91.
13. Liu, Q. Y., Rubin, M. A., Omene, C., Lederman, S., and Stein, C. A. (1998). Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin. Cancer Res. 4: 1803-1811.
14. Hedlund, T. E., Duke, R. C., Schleicher, M. S., and Miller, G. J. (1998). Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage. Prostate 36: 92-101.
15. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., and Ferguson, T. A. (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege [see comments]. Science 270: 1189-1192.
16. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R. C. (1995). A role for CD95 ligand in preventing graft rejection [see comments] [published erratum appears in Nature 394(6689):133, 1998]. Nature 377: 630-632.
17. Stuart, P. M., Griffith, T. S., Usui, N., Pepose, J., Yu, X., and Ferguson, T. A. (1997). CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99: 396-402.
18. French, L. E., et al. (1996). Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133: 335-343.
19. Suzuki, A., Matsuzawa, A., and Iguchi, T. (1996). Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 13: 31-37.
20. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. (1992). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317.
21. Frost, P., Ng, C. P., Belldegrun, A., and Bonavida, B. (1997). Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell. Immunol. 180: 70-83.
22. Hedlund, T. E., et al. (1999). Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 6: 175-182.
23. Bennett, M., Macdonald, K., Chan, S. W., Luzio, J. P., Simari, R., and Weissberg, P. (1998). Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis [see comments]. Science 282: 290-293.
24. Rubinchik, S., Ding, R., Qiu, A., Zhang, F., and Dong, J. (2000). Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther. 7: 875-885.
25. Zhang, G., Gurtu, V., and Kain, S. R. (1996). An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem. Biophys. Res. Commun. 227: 707-711.
26. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89: 5547-5551.
27. Huang, M. M., and Hearing, P. (1989). The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex. Genes Dev. 3: 1699-1710.
28. Deryckere, F., and Burgert, H. G. (1997). Rapid method for preparing adenovirus DNA. Biotechniques 22: 868-870.
29. Zhang, W. W., Koch, P. E., and Roth, J. A. (1995). Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques 18: 444-447.
30. McGahon, A. J., Nishioka, W. K., Martin, S. J., Mahboubi, A., Cotter, T. G., and Green, D. R. (1995). Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 270: 22625-22631.
31. Takahashi, S., et al. (1993). Establishment of apoptosis-inducing monoclonal antibody 2D1 and 2D1-resistant variants of human T cell lines. Eur. J. Immunol. 23:1935-1941.
32. Darzynkiewicz, Z., Juan, G., Li, X., Gorczyca, W., Murakami, T., and Traganos, F. (1997). Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27: 1-20.
33. Yonehara, S., et al. (1994). Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int. Immunol. 6: 1849-1856.
34. Uslu, R., et al. (1997). Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin. Cancer Res. 3: 963-972.
35. Rokhlin, O. W., et al. (1997). Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 57: 1758-1768.
36. Thilenius, A. R., Braun, K., and Russell, J. H. (1997). Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Eur. J. Immunol. 27: 1108-1114.
37. Zhang, X. D., Franco, A. V., Nguyen, T., Gray, C. P., and Hersey, P. (2000). Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J. Immunol. 164: 3961-3970.
38. Garcia-Mata, R., Bebok, Z., Sorscher, E. J., and Sztul, E. S. (1999). Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. 146: 1239-1254.
39. Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998). Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 143: 1883-1898.
40. Fleming, T. P., Matsui, T., Molloy, C. J., Robbins, K. C., and Aaronson, S. A. (1989). Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc. Natl. Acad. Sci. USA 86: 8063-8067.
41. Muruve, D. A., Nicolson, A. G., Manfro, R. C., Strom, T. B., Sukhatme, V. P., and Libermann, T. A. (1997). Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet alloqrafts and isografts. Hum. Gene Ther. 8: 955-963.
42. Martinez-Lorenzo, M. J., et al. (1999). Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol. 163: 1274-1281.
43. Yamashita, H., Otsuki, Y., Ito, Y., Matsumoto, K., Ueki, K., and Ueki, M. (1999). Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle. Mol. Hum. Reprod. 5(4): 358-364.